| Ytd | -66.80% | |
| 1y | -66.60% |
| Open | 1.74 | Prev Close | 1.74 | Low | 1.67 | High | 1.75 | Mkt Cap | 221.32M |
| Vol | 638.40K | Avg Vol | 808.35K | EPS | -0.79 | P/E | N/A | Forward P/E | -79.50 |
| Beta | 1.60 | Short Ratio | 11.35 | Inst. Own | 48.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 2.24 | 200-d Avg | 3.21 | 1yr Est | 5.00 |
ORGO News
Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session.
Truist Securities analyst Ravi Misra maintains Organogenesis Holdings (NASDAQ:ORGO) with a Hold a
Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The
US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after wea
Atlassian Corp (NASDAQ: TEAM) reported strong Q4 results, beating revenue and earnings estimates. St
Organogenesis NASDAQ: ORGO reported a sharp year-over-year decline in second-quarter revenue as the
Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript
Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market
Organogenesis Holdings (NASDAQ:ORGO) lowers FY2026 sales outlook from $270.000 million-$310.000 mill
CANTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leadi
CANTON, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leadi
Pegasystems Inc (NASDAQ: PEGA) reported lower-than-expected earnings and sales, causing stocks to fa
US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading
US stock futures higher with Nasdaq 100 up 150 points. Ryanair (RYAAY) shares fall after weak Q1 res
CANTON, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leadi
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on produ
CANTON, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leadi
Organogenesis is grappling with significant revenue declines in 2026 due to adverse Medicare policy
Top analysts change outlook on top names. Check out analyst ratings page for all changes. RMIX, ABSI
Truist Securities analyst Ravi Misra initiates coverage on Organogenesis Holdings (NASDAQ:ORGO) w
Estee Lauder (EL) shares jumped 11.8% in pre-market trading after ending discussions with Puig. Othe
U.S. stock futures rise with Dow gaining 300 points. Deckers Outdoor Corp shares fall after beating
Organogenesis NASDAQ: ORGO reported a sharp year-over-year revenue decline in the first quarter of 2
U.S. stock futures up, Dow futures gain approx. 100 pts. Forward Air Corp (FWRD) shares down 42.8% i
U.S. stock futures up, Dow futures gain approx. 100 pts. Forward Air Corp (FWRD) shares down 42.8% i
Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript
Organogenesis Holdings (NASDAQ:ORGO) lowers FY2026 sales outlook from $350.000 million-$420.000 mill
Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly losses of $(0.34) per share which missed the an
CANTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leadin
If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain I
Wound closure at 12 weeks was a key highlight, indicating the product's efficacy.
Organogenesis stock rises after PuraPly AM trial shows improved diabetic foot ulcer closure; RSI sig
Organogenesis Holdings Inc. is a cash-generative wound care leader trading at distressed multiples d
The trial demonstrated statistically significant wound closure at 12 weeks when comparing PuraPly AM
Organogenesis stock jumps after PuraPly AM trial meets endpoint, while ReNu shows mixed Phase 3 data
SILO stock rose 51.8% in pre-market trading after its PTSD treatment pipeline received a patent from
Statistically significant (p<0.0477) DFU wound closure at 12 weeksRCT compared PuraPly®AM plus st
CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a lead
Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the de
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CAN
CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a lead
SG Americas Securities LLC raised its holdings in Organogenesis (NASDAQ: ORGO) by 199.4% during the
BTIG analyst Ryan Zimmerman reiterates Organogenesis Holdings (NASDAQ:ORGO) with a Buy and mainta
BTIG analyst Ryan Zimmerman maintains Organogenesis Holdings (NASDAQ:ORGO) with a Buy and lowers
Organogenesis Holdings Inc. (ORGO) Q4 2025 Earnings Call Transcript
Organogenesis Holdings (NASDAQ:ORGO) sees FY2026 sales of $350.000 million-$420.000 million vs $543.
